Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab vs Fumaric Acid Esters in Plaque Psoriasis
NCT02951533Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Started Dec 2016; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02951533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951533.